Targeting hexokinase 2 for oral cancer therapy: structure-based design and validation of lead compounds.

Abstract

The pursuit of small molecule inhibitors targeting hexokinase 2 (HK2) has significantly captivated the field of cancer drug discovery. Nevertheless, the creation of selective inhibitors aimed at specific isoforms of hexokinase (HK) remains a formidable challenge. Here, we present a multiple-pharmacophore modeling approach for designing ligands against HK2 with a marked anti-proliferative effect on FaDu and Cal27 oral cancer cell lines. Molecular dynamics (MD) simulations showed that the prototype ligand exhibited a higher affinity towards HK2. Complementing this, we put forth a sustainable synthetic pathway: an environmentally conscious, single-step process facilitated through a direct amidation of the ester with an amine under transition-metal-free conditions with an excellent yield in ambient temperature, followed by a column chromatography avoided separation technique of the identified lead bioactive compound (H2) that exhibited cell cycle arrest and apoptosis. We observed that the inhibition of HK2 led to the loss of mitochondrial membrane potential and increased mitophagy as a potential mechanism of anticancer action. The lead H2 also reduced the growth of spheroids. Collectively, these results indicated the proof-of-concept for the prototypical lead towards HK2 inhibition with anti-cancer potential.

• Authors: Purbali Chakraborty, Syeda Lubna, Shouvik Bhuin, Deepika K, Manab Chakravarty, Trinath Jamma, Perumal Yogeeswari
• Journal: Frontiers in pharmacology (Front Pharmacol) Vol. 15 Pg. 1346270 ( 2024) ISSN: 1663-9812 [Print] Switzerland
• PMID: 38529190 (Publication Type: Journal Article)
• Copyright: Copyright © 2024 Chakraborty, Lubna, Bhuin, K., Chakravarty, Jamma and Yogeeswari.